VAXART INC (VXRT)
US92243A2006 - Common Stock
VXRT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of VXRT have multiple concerns. VXRT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VXRT had negative earnings in the past year.
In the past year VXRT has reported a negative cash flow from operations.
In the past 5 years VXRT always reported negative net income.
VXRT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -89.80%, VXRT is not doing good in the industry: 74.40% of the companies in the same industry are doing better.
The Return On Equity of VXRT (-142.66%) is worse than 64.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.8% | ||
| ROE | -142.66% | ||
| ROIC | N/A |
ROA(3y)-63.92%
ROA(5y)-52.63%
ROE(3y)-92.58%
ROE(5y)-89.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VXRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VXRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VXRT has been increased compared to 1 year ago.
The number of shares outstanding for VXRT has been increased compared to 5 years ago.
The debt/assets ratio for VXRT is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.45, we must say that VXRT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.45, VXRT is doing worse than 68.09% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that VXRT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, VXRT is in line with its industry, outperforming 40.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.45 |
ROIC/WACCN/A
WACC8.98%
2.3 Liquidity
A Current Ratio of 3.32 indicates that VXRT has no problem at all paying its short term obligations.
VXRT's Current ratio of 3.32 is on the low side compared to the rest of the industry. VXRT is outperformed by 62.97% of its industry peers.
VXRT has a Quick Ratio of 3.32. This indicates that VXRT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.32, VXRT is doing worse than 61.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.32 | ||
| Quick Ratio | 3.32 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.95% over the past year.
The Revenue has grown by 6613.64% in the past year. This is a very strong growth!
VXRT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.93% yearly.
EPS 1Y (TTM)30.95%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q33.33%
Revenue 1Y (TTM)6613.64%
Revenue growth 3Y22.64%
Revenue growth 5Y11.93%
Revenue growth Q2Q16125%
3.2 Future
Based on estimates for the next years, VXRT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.85% on average per year.
Based on estimates for the next years, VXRT will show a very strong growth in Revenue. The Revenue will grow by 90.01% on average per year.
EPS Next Y20.28%
EPS Next 2Y14.38%
EPS Next 3Y12.85%
EPS Next 5YN/A
Revenue Next Year375.27%
Revenue Next 2Y172.98%
Revenue Next 3Y180%
Revenue Next 5Y90.01%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VXRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VXRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VXRT's earnings are expected to grow with 12.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.38%
EPS Next 3Y12.85%
5. Dividend
5.1 Amount
VXRT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VAXART INC
NASDAQ:VXRT (5/3/2024, 7:25:53 PM)
After market: 0.7401 +0.01 (+1.54%)0.7289
-0.02 (-2.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap128.90M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.8% | ||
| ROE | -142.66% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.32 | ||
| Quick Ratio | 3.32 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)30.95%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y20.28%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6613.64%
Revenue growth 3Y22.64%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y